Recommendations for the treatment of Crohn's disease with tumor necrosis factor antagonists: An expert consensus report

BG Feagan, M Lemann, R Befrits, W Connell, G D'Haens, S Ghosh, P Michetti, T Ochsenkuhn, R Panaccione, S Schreiber, M Silverberg, D Sorrentino, C.J. van der Woude, S Vermeire, P Rutgeerts

Research output: Contribution to journalArticleAcademicpeer-review

61 Citations (Scopus)


Background: Symptom relief is the traditional treatment goal in Crohn's disease (CD). New goals including mucosal healing and bowel preservation are now achievable with tumor necrosis factor (TNF) antagonists. Infliximab and adalimumab are approved as second-line treatments for severe, active CD. Certolizumab pegol is approved only in the U.S. and Switzerland as second-line treatment for moderate-to-severe, active CD. Data from trials of infliximab suggest that high-risk patients and patients with active inflammation (CRP elevation and/or ileocolonic ulcers) may benefit from earlier use of this drug.
Original languageUndefined/Unknown
Pages (from-to)152-160
Number of pages9
JournalInflammatory Bowel Diseases
Issue number1
Publication statusPublished - 2012

Cite this